Sector Expert: Ran Nussbaum

Pontifax

Image: Ran Nussbaum

Ran Nussbaum is a managing partner and co-founder of The Pontifax Group, which has established four funds with more $370M under management and more than 45 portfolio companies. Over the past eight years, Nussbaum has managed the group's activity alongside Tomer Kariv. He also served as CEO of Biomedix and was NasVax Ltd.'s chairman of the board. Prior to joining Pontifax, he was a partner at Israel's largest business intelligence and strategic consulting firm. Nussbaum's work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Nussbaum serves as a board member of many of the Pontifax Group's portfolio companies, including TheraCoat, CollPlant Ltd., Quiet Therapeutics, Fusimab Ltd. and OCON Medical Ltd., where he is currently chairman of the board.



Recent Quotes

"We believe ARNI is very good story for prostate and breast cancer indications."

The Life Sciences Report Interview with Ran Nussbaum (9/2/15)
more >

"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation."

The Life Sciences Report Interview with Ran Nussbaum (4/3/14)
more >

"ARNI's Onapristone will have a real nice chance in the prostate cancer market."

The Life Sciences Report Interview with Ran Nussbaum (8/22/13)
more >



Due to permission requirements, not all quotes are shown.